Vimarsana
Biggest News Aggregation in the World

Page 46 - Aser Surgery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aser Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aser Surgery Today - Breaking & Trending Today

Embracing the Inevitability of Aging With a Health System That Supports Doing So Gracefully - Vimarsana News

Embracing the Inevitability of Aging With a Health System That Supports Doing So Gracefully

By adopting integrated care models, providers and payors can ensure a seamless continuum of care for older adults.

Counteract Primary Care Clinician Burnout Through Psychiatric Collaborative Care - Vimarsana News

Counteract Primary Care Clinician Burnout Through Psychiatric Collaborative Care

The psychiatric collaborative care model offers an opportunity to mitigate burnout by reducing the burden placed on primary care providers (PCPs) and more effectively supporting their patients with behavioral health needs.

TBD Health Partners with Wisp, FOLX Health To Offer Access to Testing and Diagnostics - Vimarsana News

TBD Health Partners with Wisp, FOLX Health To Offer Access to Testing and Diagnostics

TBD Health is moving into the B2B healthcare space by partnering with digital health companies, starting with FOLX Health and Wisp.

How Can AI Support Value-Based Care? - Vimarsana News

How Can AI Support Value-Based Care?

During a panel discussion at CES 2024, health executives shared safe ways AI can be used to support value-based care. This includes automating tasks and predicting who needs additional care.

Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B - Vimarsana News

Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B

BridgeBio will receive $500 million in exchange for royalties from sales of acoramidis, a drug currently under FDA review for treating heart complications caused by the rare disease transthyretin amyloidosis. The deal also refinances lending agreements, providing BridgeBio with access to additional capital.